entertainment -WSS

entertainment

author：fashion 2025-08-28 03:34:34 - browse：1282

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Florida babysitter arrested over hot car death, authorities say

focus

WSS

Judge denies Trump's request for new trial in E. Jean Carroll case

Caribou posts encouraging results on off

Hormonal contraceptives don’t actually treat endometriosis

Are infertility treatments 'essential' during the Covid

Why the advice to take all your antibiotics may be wrong

Hormonal contraceptives don’t actually treat endometriosis

hotspot

entertainment

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Trump Organization, Michael Cohen agree to settle million

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hormonal contraceptives don’t actually treat endometriosis

Bright Health sells Medicare Advantage business to Molina

Are infertility treatments 'essential' during the Covid

focus

It's time to take a new tack for treating Alzheimer's

Extensive review finds private equity owners jack up cost of care

Prosecutors say FTX founder Sam Bankman

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

knowledge

focus

focus

hotspot